A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581 · SUNRAY-01 Phase 3Recruiting
- Lead sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 1,264 (estimated)
- Start date
- 21 Dec 2023
- Primary completion
- Nov 2027 (estimated)
- Study completion
- 1 Jan 2031
- Last update posted
- 7 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 8
Interventions
- LY3537982 Drug
- Pembrolizumab Drug
- Placebo Drug
- Cisplatin Drug
- Carboplatin Drug
- Pemetrexed Drug
Conditions and primary outcome
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
Primary outcome
Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE) (Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)); Part A and Part B: Progression-Free Survival (PFS) (Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedSUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.
Future oncology (London, England) · 2026 Apr
PubMed 41940628 (opens in a new tab)DOI 10.1080/14796694.2026.2651961 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06119581 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.